印度制药公司和新兴市场的机会，全球战略：以Aurobindo制药公司的案例研究
目的：为了了解印度制药公司最近走向全球的趋势，他们在海外投资以扩大市场。
目标：了解印度制药行业的优势，分析全球各公司的并购模式。
语境：这项研究包括印度新兴制药公司的战略，并了解正在走向全球的公司在全球扩大市场的趋势和过程。
文献综述：在世界制药行业，印度在数量上占第四，在价值方面排名第十三。2006年度的价值为74亿2000万美元，比上一年增长了12.9%。在销售总额中，90%的销售额被列为仿制药，其余的都是专利药品。现在，世界各国政府、病人和工业界都在关注仿制药，因为它们的成本较低，研发投入较少，与专利药物相比。在2005，仿制药市场已增加了20%，是专利药的四倍，是药品市场的三倍。美国市场就已经获得仿制药44%。年复合增长率（CAGR）在印度药品仿制药品已年期间增加了16.6%。预计年复合增长率为2009-2014年期间是13.2%，大约总价值可能达到2014美元15490m。2009年，在印度有超过80个FDA批准的植物，意大利（55）和中国（27）。印度制药公司Cipla公司一样，Reddy博士的实验室；Wockhardt、Lupin和Nicholas Piramal是在发达市场如美国和欧洲做的很好。这些公司在配方、大宗药物、仿制药、新的药物输送系统、新的化学实体、生物技术等方面有着令人兴奋的价值。
Global strategy for Indian pharmacy companies and the opportunity in emerging markets: A case study on Aurobindo Pharma
Focus
Aim:
To understand the trends in Indian pharmacy companies which have been recently going global by investing abroad with an intention for market expansion?
Objectives:
To find out the strengths of the Indian Pharmaceutical Industry and analyse the pattern of Mergers and Acquisitions by various companies across the globe.
To throw light on the strategies followed by Aurobindo Pharma in acquiring other pharma companies.
Context
The research includes strategy of the emerging pharmaceutical companies in India and understands the trends and process of the companies that have been going global to expand their market in the world-wide.
Literature review:
In pharmaceutical sector around the world, India ranks 4th in terms of volume and 13th in terms of value. In the year 2006 the value was USD 7.42 billion, the growth has been increased by 12.9% over the previous year. In this total sales 90% of the sales are accounted as generics and the remaining are patented drugs. Now a day’s governments of various countries, patients and industries are pulling attention towards generic drugs, due to lower in cost and less R&D investment than compares to that of the patented drugs. In the year 2005 the generic market has been increased by 20% in the world which is four times that of the patented drugs and three times that of the pharmaceuticals market. US market alone had acquired 44% of the generic drugs (Pharmabiz, 2009). The Compound Annual Growth Rate (CAGR) of generic drugs in Indian pharmaceuticals has been increased by 16.6% during the period of 2001-05. The expected CAGR during the period of 2009-14 would be 13.2% and approximately the total value may reach $15,490m in 2014 (Research and Markets, 2009). In the year 2009 in India there were more than 80 FDA approved plants, Italy (55) and China (27). The Indian pharmaceuticals companies like Cipla, Dr. Reddy’s lab; Wockhardt, Lupin and Nicholas Piramal are doing well in developed market such as US and Europe. These companies have exciting values in formulation, bulk drugs, generics, novel drug delivery system, new chemical entities, biotechnology etc (Research and Markets, 2007).
4.1 Indian pharmaceutical market structure:
Source: Cygnus, 2007
According to Dr. Richard Gerster, “The Indian pharmaceutical industry is a success story providing employment for millions and ensuring that essential drugs at affordable prices are available to the vast population of this sub-continent.The Indian pharmaceuticals ranks very high in terms of quality, technology and the range of medicines manufactured. Indian pharmaceuticals market will grow 10-14%, to touch $40 billion by 2015 (Mckinsey, 2009).
India has a powerful biotechnology that can overthrow by the revolution of agriculture, healthcare, industrial processing and environmental sustainability. In India there are 100 research laboratories and more than 400 educational and training institutes across the country (Pharma India, 2005).
Major companies in India 2006
Source: company annual report FY 2006-07, *annual report 2006 December ending.
In the above figure y-axis indicates to turnover (Rs.bn)
Indian pharmaceuticals is divided into two benefits, one is strong domestic consumption growth and robust export opportunities (Indus view, 2009).
4.2 Mergers
